Clinical effect not specified
Source: DDInter
COMT Inhibitor · Antiparkinsonian
Tolcapone prevents the peripheral breakdown of levodopa by inhibiting catechol-O-methyltransferase (COMT). This action increases the bioavailability of levodopa, allowing a greater amount to reach the brain where it can be converted to dopamine.
Toxicity in animal studies. Use only if potential benefit outweighs risk.
Avoid; present in milk in animal studies.
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team